A complementary new drug for PNH

Research output: Contribution to journalArticlepeer-review


In this issue of Blood, Röth et al show in a phase 1/2 trial that crovalimab, a subcutaneously administered monoclonal antibody that targets C5, is safe and effective in treating paroxysmal nocturnal hemoglobinuria (PNH).1 Crovalimab targets a C5 epitope that is different from the IV C5 inhibitors, eculizumab and ravulizumab. Crovalimab is administered subcutaneously every 4 weeks.

Original languageEnglish (US)
Pages (from-to)884-885
Number of pages2
Issue number12
StatePublished - Mar 19 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'A complementary new drug for PNH'. Together they form a unique fingerprint.

Cite this